Adipotide

Product Description

Adipotide is an experimental synthetic peptide that was developed as a targeted treatment for obesity. It is not a clinically approved drug, and it is not a natural hormone, steroid, or dietary supplement. It belongs to a class of experimental compounds called prohibitins-targeted apoptosis-inducing peptides, designed to selectively destroy the blood vessels that supply adipose tissue (body fat).

Molecular structure and mechanism of action

Adipotide is a chimeric peptide consisting of two functional parts:

1. A homing domain – a cyclic peptide (amino acid sequence CKGGRAKDC) that specifically binds to prohibitin, a protein expressed on the surface of the endothelial cells lining the blood vessels of adipose tissue. This binding is tissue-selective, meaning the peptide localizes to fat vasculature rather than most other tissues.
2. An apoptotic domain – a pro-apoptotic peptide sequence (KLAKLAK)₂, which, once internalized by the endothelial cell, disrupts the inner mitochondrial membrane, triggering apoptosis (programmed cell death).

By inducing apoptosis in the vascular endothelium of adipose tissue, Adipotide effectively cuts off the blood supply to fat cells, causing them to shrink and be cleared by the body. This mechanism is fundamentally different from that of traditional weight-loss drugs or anabolic steroids; it causes a reduction in fat mass through vascular disruption, rather than by altering metabolism centrally or blocking dietary absorption.

Development history and research status

Adipotide was developed by researchers Renata Pasqualini and Wadih Arap, originally at the MD Anderson Cancer Center (University of Texas). The theoretical foundation was that anti-angiogenic (blood-vessel-blocking) agents could be used to destroy fat tissue, much like similar strategies used in cancer therapy.

• Preclinical mouse studies: Adipotide markedly reduced body fat in obese mice, with associated improvements in insulin sensitivity and blood glucose levels.
• Non-human primate study (2011, Science Translational Medicine): An effectiveness and safety trial in obese rhesus monkeys showed statistically significant reduction in body fat (roughly 30–40% fat loss in the treated group) along with reduced body weight. However, the monkeys in the study developed kidney toxicity, including elevations in blood urea nitrogen, creatinine, and reduced glomerular filtration. Some individuals showed signs of proteinuria and renal damage.
• Human trials: As of current medical knowledge, Adipotide has not progressed to approved human clinical trials for obesity, and there is no licensed human use. Its clinical development has reportedly stalled due to toxicity concerns, lack of funding, and/or lack of translation to a safe therapeutic window.

Routes of administration and dosage

In research settings, Adipotide is typically given by subcutaneous injection. Doses in animal studies were usually in the range of 1–10 mg/kg every day or every other day for several weeks, but there is never a validated human dosing schedule. It is supplied for research purposes as a lyophilized powder that must be reconstituted with a suitable solvent (e.g., sterile water or saline) and used quickly, as the peptide is unstable.

Adverse effects and safety profile

As an experimental peptide, the full safety profile is unknown. Documented risks include:

• Nephrotoxicity (kidney damage) – This is the most significant observed side effect, occasionally acute and potentially irreversible. The exact mechanism is not fully understood but is thought to involve off-target effects on renal vasculature or metabolic consequences of rapid fat breakdown.
• Injection-site reactions – Local pain, redness, and inflammation are common.
• Systemic toxicity – Potential for fever, fatigue, and malaise, particularly with higher doses.
• Electrolyte disturbances – Rapid fat loss can cause metabolic shifts, including altered potassium and glucose levels.
• Hypotension – A drop in blood pressure has been reported in some research models.
• Unknown long-term effects – Because prolonged human exposure studies do not exist, chronic effects on cardiovascular, endocrine, and immune systems cannot be characterized.

Legality and availability

Adipotide is not a controlled substance (like anabolic steroids) in most jurisdictions, but it is also not an approved medicine. It is sold illegally in some underground markets as a “peptide research chemical.” Possession, sale, or use for human consumption is prohibited or unlicensed in most countries. Because it is not manufactured by legitimate pharmaceutical companies, there is no quality control; products labeled “Adipotide” may contain incorrect amounts, impurities, degradation products, or completely different substances. It is not a dietary supplement, nor a cosmetic, and any claim that it can be used for safe weight loss is unsupported by regulatory agencies.

Important caveats

• No approved human indication: Adipotide has not passed the stringent safety and efficacy testing required by the FDA, EMA, or equivalent bodies anywhere in the world.
• Serious risk of kidney injury: Observed toxicities in animal models are disqualifying for use outside a formal and ethically approved clinical trial.
• Not a fat-burner in the traditional sense: It works by destroying fat vasculature, a highly experimental and potentially dangerous mechanism. It does not stimulate thermogenesis or lipolysis.